Skip to main content
Clinical Trials/NCT06442189
NCT06442189
Completed
Not Applicable

Prospective Evaluation of the Effects of the Mediterranean Diet on the Reproductive and Metabolic Parameters of Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) and a Body Mass Indexof Over 25 kg/m2

Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital1 site in 1 country98 target enrollmentSeptember 20, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Polycystic Ovary Syndrome
Sponsor
Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital
Enrollment
98
Locations
1
Primary Endpoint
the effect of applying a Mediterranean diet on Homa-IR in PCOS
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month in patients with a body mass index of 25 and more who were followed up in our clinic due to a PCOS diagnosis.

Detailed Description

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by menstrual irregularities, anovulation, clinical and/or biochemical symptoms of hyperandrogenism (hirsutism and/or acne), micropolycystic ovaries and metabolic abnormalities. Phenotype A: HA + OD + PCOM; phenotype B: HA + OD; phenotype C: HA + PCOM and phenotype D: OD + PCOM). According to the Rotterdam criteria, endocrine and metabolic abnormalities are lowest in the OD + PCOM group among these 4 different phenotype groups. The prevalence and distribution of metabolic abnormalities (insulin resistance, metabolic disease and glucose intolerance) among the phenotypes do not differ significantly between the 4 groups. Therefore, metabolic abnormalities and distribution characteristics are not suitable to distinguish different clinical PCOS phenotypes. Some inflammatory cytokines are elevated in PCOS, which is characterized by chronic low-grade inflammation. Although the exact mechanisms of inflammation in PCOS are not yet fully understood, it is thought to be mediated by obesity, insulin resistance and high androgen levels. This inflammatory state has a negative impact on the risk of future health problems and quality of life in PCOS. Therefore, strategies to reduce inflammation are considered important. Establishing medical nutrition therapy for PCOS has significant implications for reducing this inflammation and preventing the disease. At this point, the Mediterranean diet, which has been shown to have a protective effect against many diseases, is receiving a lot of attention. Among the components of the Mediterranean diet, omega-3 fatty acids, antioxidants and fiber in particular can contribute to reducing inflammation through various mechanisms. The international scientific community has strongly emphasized the role of the Mediterranean diet and the lifestyle it inspires in increasing life expectancy and improving public health. For these reasons, the Mediterranean diet can be considered as a nutrient pool containing nutraceuticals and bioactive components in foods that can positively influence health both directly and through their own epigenetic mechanisms. Recent studies suggest that the Mediterranean diet can influence both the incidence and severity of PCOS and the treatment of the disease. The main objective of our study is to evaluate the effect of the MedDiet, which is known to be anti-inflammatory and based on energy restriction and the Mediterranean dietary approach, on the reproductive and metabolic parameters of PCOS patients with a higher than normal body mass index.

Registry
clinicaltrials.gov
Start Date
September 20, 2024
End Date
November 11, 2024
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Mujde Can Ibanoglu

Assoc. Prof

Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • At the age of 18-40 years,
  • No underlying metabolic disease (type 2 diabetes, hypertension, diagnosed anemia),
  • With a body mass index of 25 and above,
  • Female patients attending the PCOS clinic and under the care of our hospital's dietitian will be enrolled in the study.

Exclusion Criteria

  • Age \< 18 and \> 40 years;
  • Menopause, pregnancy or breastfeeding in the last 6 months;
  • Hyperandrogenism and/or biochemical hyperandrogenemia due to secondary etiologies, including congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome, hyperprolactinemia, thyroid dysfunction and adrenal disorders),
  • Pre-existing systemic or psychiatric disease
  • Use of drugs that affect carbohydrate or lipid metabolism (oral contraceptive pills, metformin, anti-epileptics, antipsychotics, statins and fish oil);
  • Certain eating regimens or hypocaloric diet in the last three months; supplementing with antioxidants, vitamins or minerals;
  • Non-steroidal anti-inflammatory drugs, diuretics, etc. use of medications that may affect fluid balance
  • Female patients with implanted pacemakers or defibrillators due to the theoretical possibility of interference with device activity.

Outcomes

Primary Outcomes

the effect of applying a Mediterranean diet on Homa-IR in PCOS

Time Frame: 3 months

Homeostasis model assessment (HoMA)-IR

the effect of applying a Mediterranean diet on HbA1c in PCOS

Time Frame: 3 months

HbA1c values

the effect of applying a Mediterranean diet on glucose in PCOS

Time Frame: 3 months

Fasting plasma glucose

PREDIMED in PCOS

Time Frame: 3 months

PREDIMED questionnaire

Study Sites (1)

Loading locations...

Similar Trials